FDA's final guidance on psychedelic drug trials names 12 months of blinded follow-up the most informative design
- The U.S. Food and Drug Administration (Center for Drug Evaluation and Research, Division of Psychiatry) issued the final version of "Psychedelic Drugs: Considerations for Clinical Investigations" in July 2026, replacing the draft of June 26, 2023; the recommendations are nonbinding and address sponsors of trials under an investigational new drug application, academic researchers included.
- Psychedelic drug programs are subject to "the same regulations and same evidentiary standards for approval as other drug development programs"; because of functional unblinding, a traditional placebo "can be problematic" for assessing efficacy.
- For chronic illnesses such as post-traumatic stress disorder or major depressive disorder, sponsors should evaluate treatment at 12 weeks with a double-blind design before an initial application and keep following participants beyond Week 12; the most informative design would add blinded follow-up (typically 12 months) with prespecified retreatment criteria.
- The contribution of the psychotherapy component "has not been characterized"; the guidance asks for two monitors throughout each treatment session and, if the lead monitor is not a physician, a licensed on-call physician able to reach the site within 15 minutes.
The U.S. Food and Drug Administration published the final version of its psychedelic drug trial guidance in July 2026, replacing the 2023 draft. Its recommendations are nonbinding and addressed to sponsors, academic researchers among them. The document begins with a plain statement: these programs are subject to "the same regulations and same evidentiary standards for approval as other drug development programs."
Blinding, controls and the session
The guidance starts from functional unblinding. Because the drugs often produce intense perceptual changes, patients, therapists, monitors and raters may infer who received what, and a traditional placebo "can be problematic" for assessing efficacy. The monitoring therapist "can usually deduce" the assignment, so one named option is to keep the in-session monitor out of post-session psychotherapy. The contribution of the psychotherapy component "has not been characterized"; a factorial design may help separate it from the drug.
Two monitors stay for the whole session: a lead with graduate-level psychotherapy training, licensed to practice independently, and an assistant with at least one year of clinical experience. If the lead is not a physician, a licensed physician is to be on call within 15 minutes.
How long the effect is followed
For chronic conditions such as post-traumatic stress disorder or major depressive disorder, the guidance places the double-blind evaluation at 12 weeks, before an initial application, and asks sponsors to keep following participants past that point. The most informative design, it says, would add blinded follow-up (typically 12 months) with prespecified retreatment criteria that count symptom ratings and whether a participant seeks other treatment outside the study. The stated reason: many of the targeted conditions typically persist for months or years.
Work with chronic conditions is often counted in years, and the retreatment criterion is close to a signal practice already reads: a client who comes back. The guidance sets the horizon of a trial, not of care.
The blinded endpoint sits at 12 weeks and the most informative follow-up at typically 12 months, while many of the conditions themselves, the guidance notes, persist for months or years.
The document is a set of nonbinding recommendations for sponsors of trials run under an investigational new drug application, not a standard of treatment outside trials. The 12-month follow-up is described as the most informative design, not as a requirement, and the guidance states that the dosing paradigm for these drugs has yet to be established.